Valeant Pharmaceuticals International, Inc. (VRX) Earns “Sell” Rating from Piper Jaffray Companies

Piper Jaffray Companies reaffirmed their sell rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a report released on Friday morning. They currently have a $12.00 price target on the specialty pharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on VRX. HC Wainwright reaffirmed a hold rating and issued a $17.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Thursday, November 9th. Canaccord Genuity set a $14.00 target price on shares of Valeant Pharmaceuticals International and gave the stock a hold rating in a report on Thursday, August 10th. Wells Fargo & Company reiterated an underperform rating and issued a $8.00 target price on shares of Valeant Pharmaceuticals International in a report on Saturday, September 30th. Jefferies Group LLC reiterated a buy rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Finally, Rodman & Renshaw reiterated a neutral rating and issued a $17.00 target price on shares of Valeant Pharmaceuticals International in a report on Thursday, August 10th. Five research analysts have rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $17.22.

Valeant Pharmaceuticals International (VRX) opened at $14.60 on Friday. The stock has a market cap of $5,361.34, a P/E ratio of 2.50, a PEG ratio of 0.43 and a beta of -0.40. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 4.84. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $18.71.

COPYRIGHT VIOLATION NOTICE: “Valeant Pharmaceuticals International, Inc. (VRX) Earns “Sell” Rating from Piper Jaffray Companies” was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/14/valeant-pharmaceuticals-international-inc-vrx-earns-sell-rating-from-piper-jaffray-companies.html.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now directly owns 77,479 shares in the company, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 5.87% of the company’s stock.

Several large investors have recently added to or reduced their stakes in VRX. Ameriprise Financial Inc. raised its position in shares of Valeant Pharmaceuticals International by 31.3% in the first quarter. Ameriprise Financial Inc. now owns 44,149 shares of the specialty pharmaceutical company’s stock valued at $487,000 after purchasing an additional 10,534 shares during the period. Alliancebernstein L.P. raised its position in shares of Valeant Pharmaceuticals International by 49.3% in the first quarter. Alliancebernstein L.P. now owns 39,664 shares of the specialty pharmaceutical company’s stock valued at $437,000 after purchasing an additional 13,092 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Valeant Pharmaceuticals International by 33.7% in the first quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the period. Vanguard Group Inc. raised its position in shares of Valeant Pharmaceuticals International by 9.8% in the first quarter. Vanguard Group Inc. now owns 6,980,074 shares of the specialty pharmaceutical company’s stock valued at $76,990,000 after purchasing an additional 621,618 shares during the period. Finally, Paloma Partners Management Co raised its position in shares of Valeant Pharmaceuticals International by 12.0% in the first quarter. Paloma Partners Management Co now owns 27,996 shares of the specialty pharmaceutical company’s stock valued at $310,000 after purchasing an additional 2,996 shares during the period. 46.61% of the stock is currently owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply